Progression of chronic kidney disease: Adrenergic genetic influence on glomerular filtration rate decline in hypertensive nephrosclerosis

American Journal of Nephrology

Volumn 32, Issue 1, 2010, Pages 23-30

  Chen, Yuqing ^g   Lipkowitz, Michael S ^b   Salem, Rany M ^a   Fung, Maple M ^a   Bhatnagar, Vibha ^a   Mahata, Manjula ^a   Nievergelt, Caroline M ^a   Rao, Fangwen ^a   Mahata, Sushil K ^a,e   Schork, Nicholas J ^c   Hicks, Pamela J ^f   Bowden, Donald W ^f   Freedman, Barry I ^f   Brophy, Victoria H ^d   O'Connor, Daniel T ^a,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d ROCHE MOLECULAR SYSTEMS   (United States)

^e VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

^g PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Adrenergic genetic influence; African American Study of Kidney Disease; Chronic kidney disease; End stage renal disease; Glomerular filtration rate; Hypertensive nephrosclerosis

Indexed keywords

AMLODIPINE; ARGININE; BETA 2 ADRENERGIC RECEPTOR; CLONIDINE; DOXAZOSIN MESYLATE; FUROSEMIDE; GENOMIC DNA; GLYCINE; HYDRALAZINE; METOPROLOL; MINOXIDIL; RAMIPRIL; ANTIHYPERTENSIVE AGENT;

ADULT; AFRICAN AMERICAN; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIPLOIDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE INCREASE; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC CORRELATION; GENETIC RISK; GENETIC TRAIT; GENETIC VARIABILITY; GLOMERULUS FILTRATION RATE; HAPLOTYPE; HUMAN; HYPERTENSION; HYPERTENSIVE NEPHROSCLEROSIS; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; NEGRO; NEPHROSCLEROSIS; NORADRENERGIC SYSTEM; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; DRUG EFFECTS; DRUG RESISTANCE; ETHNOLOGY; GENETICS; HYPERTENSION, RENAL; MIDDLE AGED; MULTICENTER STUDY (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL INSUFFICIENCY, CHRONIC; YOUNG ADULT;

ADULT; AFRICAN AMERICANS; AGED; ANTIHYPERTENSIVE AGENTS; DISEASE PROGRESSION; DRUG RESISTANCE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION, RENAL; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEPHROSCLEROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ADRENERGIC, BETA-2; RENAL INSUFFICIENCY, CHRONIC; YOUNG ADULT;

EID: 77952307538     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000313927     Document Type: Article

References (50)

1. Rahman M, Douglas JG, Wright JT Jr: Pathophysiology and treatment implications of hypertension in the African-American population. Endocrinol Metab Clin North Am 1997;26:125-144.
2. Ferguson R, Grim CE, Opgenorth TJ: A familial risk of chronic renal failure among Blacks on dialysis? J Clin Epidemiol 1988;41: 1189-1196.
3. Freedman BI, Spray BJ, Tuttle AB, Buckalew VM Jr: The familial risk of end-stage renal disease in African-Americans. Am J Kidney Dis 1993;21:387-393.
4. Freedman BI, Yu H, Anderson PJ, Roh BH, Rich SS, Bowden DW: Genetic analysis of nitric oxide and endothelin in end-stage renal disease. Nephrol Dial Transplant 2000; 15: 1794-1800.
5. Schelling JR, Zarif L, Sehgal A, Iyengar S, Se-dor JR: Genetic susceptibility to end-stage renal disease. Curr Opin Nephrol Hypertens 1999; 8:465-472.
6. Yu H, Bowden DW, Spray BJ, Rich SS, Freed-man BI: Linkage analysis between loci in the renin-angiotensin axis and end-stage renal disease in African-Americans. J Am Soc Nephrol 1996;7:2559-2564.
7. Yu H, Song Q, Freedman BI, Chao J, Chao L, Rich SS, Bowden DW: Association of the tissue kallikrein gene promoter with ESRD and hypertension. Kidney Int 2002;61:1030-1039.
8. Campese VM, Kogosov E: Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995; 25: 878-882.
9. 2O transport in Henle's loop of the rat. Am J Physiol 1982; 243:F576-F580.
10. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG: Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992;327: 1912-1918.
11. Hansen J, Victor RG: Direct measurement of sympathetic activity: new insights into disordered blood pressure regulation in chronic renal failure. Curr Opin Nephrol Hypertens 1994; 3: 636-643.
12. Amann K, Rump LC, Simonaviciene A, Oberhauser V, Wessels S, Orth SR, Gross ML, Koch A, Bielenberg GW, Van Kats JP, Ehmke H, Mall G, Ritz E: Effects of low dose sympathetic inhibition on glomerulosclero-sis and albuminuria in subtotally nephrecto- mized rats. J Am Soc Nephrol 2000; 11: 14691478.
13. 2- adrenoceptor haplo-types and age on susceptibility to hypertension and receptor function. Hypertension 2005;46:301-307.
14. 2-adrenergic receptor gene are associated with essential hypertension in a Singaporean Chinese population. J Hypertens 2004; 22: 2111-2116.
15. 2- adrenergic receptor gene is associated with essential hypertension in a population of Chinese origin. Am J Hypertens 2001; 14: 1196-1200.
16. Rao F, Wessel J, Wen G, Zhang L, Rana BK, Kennedy BP, Greenwood TA, Salem RM, Chen Y, Khandrika S, Hamilton BA, Smith DW, Holstein-Rathlou NH, Ziegler MG, Schork NJ, O'Connor DT: Renal albumin excretion: twin studies identify influences of heredity, environment, and adrenergic pathway polymorphism. Hypertension 2007; 49: 1015-1031.
17. Sharma P, Hingorani A, Jia H, Ashby M, Hopper R, Clayton D, Brown MJ: Positive association of tyrosine hydroxylase microsat-ellite marker to essential hypertension. Hypertension 1998; 32: 676-682.
18. Zhang L, Rao F, Wessel J, Kennedy BP, Rana BK, Taupenot L, Lillie EO, Cockburn M, Schork NJ, Ziegler MG, O'Connor DT: Functional allelic heterogeneity and pleiotropy of a repeat polymorphism in tyrosine hydroxy-lase: prediction of catecholamines and response to stress in twins. Physiol Genomics 2004; 19: 277-291.
19. Wright JT Jr, Kusek JW, Toto RD, Lee JY, Agodoa LY, Kirk KA, Randall OS, Glassock R: Design and baseline characteristics of participants in the African-American Study of Kidney Disease and Hypertension (A ASK) pilot study. Control Clin Trials 1996;17: 3S-16S.
20. Fogo A, Breyer JA, Smith MC, Cleveland WH, Agodoa L, Kirk KA, Glassock R: Accuracy of the diagnosis of hypertensive nephrosclerosis in African-Americans: a report from the African-American Study of Kidney Disease (AASK) trial. AASK pilot study investigators. Kidney Int 1997;51:244252.
21. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Ja-merson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER 3rd, Norris K, O'Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schul- man G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT Jr, Xu S: Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285: 27192728.
22. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, He-bert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG: Effect of blood pressure intensively lowering and an-tihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288:2421-2431.
23. Wright JT Jr, Agodoa L, Contreras G, Greene T, Douglas JG, Lash J, Randall O, Rogers N, Smith MC, Massry S: Successful blood pressure control in the African-American Study of Kidney Disease and Hypertension. Arch Intern Med 2002; 162: 1636-1643.
24. Hall WD, Kusek JW, Kirk KA, Appel LJ, Schulman G, Agodoa LY, Glassock R, Grim C, Randall OS, Massry SG: Short-term effects of blood pressure control and antihy-pertensive drug regimen on glomerular filtration rate: The African-American Study of Kidney Disease and Hypertension Pilot Study. Am J Kidney Dis 1997;29:720-728.
25. Salem R, Cadman P, Chen Y, Rao F, Wen G, Hamilton B, Rana B, Smith D, Stridsberg M, Ward H, Mahata M, Mahata S, Bowden D, Hicks P, Freedman B, Schork N, O'Connor DT: Chromogranin A polymorphisms are associated with hypertensive renal disease. J Am Soc Nephrol 2008; 19: 600-614.
26. Buetow KH, Edmonson M, MacDonald R, Clifford R, Yip P, Kelley J, Little DP, Strausberg R, Koester H, Cantor CR, Braun A: High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Proc Natl Acad Sci USA 2001;98:581-584.
27. Ahmadian A, Ehn M, Hober S: Pyrosequenc-ing: history, biochemistry and future. Clin Chim Acta 2006; 363: 83-94.
28. Cheng S, Grow MA, Pallaud C, Klitz W, Erlich HA, Visvikis S, Chen JJ, Pullinger CR, Malloy MJ, Siest G, Kane JP: A multilocus genotyping assay for candidate markers of cardiovascular disease risk. Genome Res 1999; 9:936-949.
29. Halperin E, Eskin E: Haplotype reconstruction from genotype data using imperfect phylogeny. Bioinformatics 2004; 20:18421849.
30. McKeigue PM, Carpenter JR, Parra EJ, Shriver MD: Estimation of admixture and detection of linkage in admixed populations by a bayesian approach: application to African-American populations. Ann Hum Genet 2000;64:171-186.
31. Nievergelt CM, Libiger O, Schork NJ: Generalized analysis of molecular variance. PLoS Genet 2007;3:e51.
32. Hahntow IN, Koopmans RP, Michel MC: The f2-adrenoceptor gene and hypertension: is it the promoter or the coding region or neither? J Hypertens 2006; 24: 1003-1007.
33. Johnatty SE, Abdellatif M, Shimmin L, Clark RB, Boerwinkle E: f2-Adrenergic receptor 5' haplotypes influence promoter activity. Br J Pharmacol 2002; 137: 1213-1216.
34. Kanayama N, Tsujimura R, She L, Maehara K, Terao T: Cold-induced stress stimulates the sympathetic nervous system, causing hypertension and proteinuria in rats. J Hyper-tens 1997;15:383-389.
35. King SE, Baldwin DS: Production of renal ischemia and proteinuria in man by the adrenal medullary hormones. Am J Med 1956; 20:217-224.
36. Calhoun DA, Mutinga ML, Collins AS, Wyss JM, Oparil S: Normotensive Blacks have heightened sympathetic response to cold pressor test. Hypertension 1993; 22: 801-805.
37. Light KC, Obrist PA, Sherwood A, James SA, Strogatz DS: Effects of race and marginally elevated blood pressure on responses to stress. Hypertension 1987; 10: 555-563.
38. Light KC, Sherwood A: Race, borderline hypertension, and hemodynamic responses to behavioral stress before and after β-adrenergic blockade. Health Psychol 1989; 8: 577595.
39. Parmer RJ, Cervenka JH, Stone RA, O'Connor DT: Autonomic function in hypertension. Are there racial differences? Circulation 1990;81:1305-1311.
40. Freedman BI, Hicks PJ, Bostrom MA, Cunningham ME, Liu Y, Divers J, Kopp JB, Winkler CA, Nelson GW, Langefeld CD, Bowden DW: Polymorphisms in the non-muscle my-osin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African-Americans. Kidney Int 2009; 75: 736745.
41. Chen Y, Mahata M, Rao F, Khandrika S, Courel M, Fung MM, Zhang K, Stridsberg M, Ziegler MG, Hamilton BA, Lipkowitz MS, Taupenot L, Nievergelt C, Mahata SK, O'Connor DT: Chromogranin A regulates renal function by triggering Weibel-Palade body exocytosis. J Am Soc Nephrol 2009; 20: 1623-1632.
42. Fung MM, Chen Y, Lipkowitz MS, Salem RM, Bhatnagar V, Mahata M, Nievergelt CM, Rao F, Mahata SK, Schork NJ, Brophy VH, O'Connor DT: Adrenergic f1-receptor genetic variation predicts longitudinal rate of GFR decline in hypertensive nephrosclerosis. Nephrol Dial Transplant 2009; 24: 36773686.
43. Muhlbauer B, Spohr F, Schmidt R, Osswald H: Role of renal nerves and endogenous do-pamine in amino acid-induced glomerular hyperfiltration. Am J Physiol 1997;273:f144-f149.
44. O'Connor DT, Tyrell EA, Kailasam MT, Miller LM, Martinez JA, Henry RR, Parmer RJ, Gabbai FB: Early alteration in glomerular reserve in humans at genetic risk of essential hypertension: mechanisms and consequences. Hypertension 2001; 37: 898-906.
45. Green SA, Turki J, Innis M, Liggett SB: Aminoterminal polymorphisms of the human f2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994;33:9414-9419.
46. Nakamura A, Niimi R, Imaizumi A, Yana-gawa Y: Renal effects of f2-adrenoceptor agonist and the clinical analysis in children. Pediatr Res 2007; 61: 129-133.
47. Masuo K, Katsuya T, Fu Y, Rakugi H, Ogihara T, Tuck ML: f2- and f3-adrenergic receptor polymorphisms are related to the onset of weight gain and blood pressure elevation over 5 years. Circulation 2005; 111: 3429-3434.
48. Boivin V, Jahns R, Gambaryan S, Ness W, Boege F, Lohse MJ: Immunofluorescent imaging of f1- and f2-adrenergic receptors in rat kidney. Kidney Int 2001; 59: 515-531.
49. Anderson S, Brenner BM: Intraglomerular hypertension: implications and drug treatment. Annu Rev Med 1988; 39: 243-253.
50. Sandilands A, Yeo G, Brown MJ, O'Shaughnessy KM: Functional responses of human β-adrenoceptors with defined haplotypes for the common 389R>G and 49S>G polymorphisms. Pharmacogenetics 2004;14: 343-349.